#ESMO17 roundup: Idera shares spike on early TLR9 combo data; Erytech touts pancreatic cancer PhIIb data
MADRID — Shares of Idera $IDRA shot up 20% in pre-market trading on Monday as investors caught up with an encouraging look at early-stage data for its TLR9 drug IMO-2125 with Bristol-Myers’ Yervoy. Researchers tracked a 44% response rate — 4 of 9 patients who had failed Keytruda or Opdivo. There was one complete response in the group, who faced poor odds in fighting their tumors.
Erytech red blood cell therapy promising in PhIIb pancreatic cancer study
France’s Erytech $ERYP turned up at ESMO to tout some new Phase IIb data on its red blood cell cancer therapy eryaspase in treating pancreatic cancer. Adding it to standard of care researchers say the drug hit overall survival and progress-free survival endpoints in the study. Erytech plans to meet with regulators next to map out a late-stage program.
Merck builds bigger lead for Keytruda in bladder cancer
Merck added more data to support the efficacy of its PD-1 superstar Keytruda in second-line bladder cancer. Following Roche’s big setback in this field for its rival PD-L1 drug Tecentriq, Merck is way out in front with supporting data for bladder cancer. In the latest update Keytruda cut the risk of death by 30% and beat out chemo on OS: 10.4 months compared to 7.4 months.
Incyte, Merck unveil latest ECHO-202 update
The combination of Keytruda with Incyte’s IDO1 drug epacadostat in ECHO-202 continues to be one of the most closely-watched programs in oncology. And in the latest update ahead of the pivotal researchers unveiled new data spotlighting the 56% of melanoma patients treated with the combo who responded to therapy, with responses running out a median of 45 weeks with PFS rates of 65% at six months, 52% at 12 months, and 49% at 18 months. The median PFS data hit 12.4 months.
Image credit: ESMO